Investing.com - Homology Medicines (NASDAQ: FIXX) reported third quarter EPS of $-0.570, $0.14 worse than the analyst estimate of $-0.430. Revenue for the quarter came in at $500K versus the consensus estimate of $780.5K.
Homology Medicines's stock price closed at $1.020. It is down -5.560% in the last 3 months and down -50.000% in the last 12 months.
Homology Medicines saw 3 positive EPS revisions and 0 negative EPS revisions in the last 90 days. See Homology Medicines's stock price’s past reactions to earnings here.
According to InvestingPro, Homology Medicines's Financial Health score is "fair performance".
Check out Homology Medicines's recent earnings performance, and Homology Medicines's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar